Abstract
Hypoactive sexual desire disorder (HSDD) is the most common sexual dysfunction in women, and is characterized by an absence or deficiency of sexual desire accompanied by personal distress. Bremelanotide, a melanocortin receptor agonist, is approved for the treatment of acquired, generalized HSDD in premenopausal women. The RECONNECT studies demonstrated that subcutaneous self-administration of bremelanotide, as needed, significantly improved sexual desire and decreased related personal distress in premenopausal women with HSDD.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call